BMY FDA calendar & decision history Bristol-Myers Squibb Company · 1 upcoming · 9 past FDA decisions
Upcoming FDA catalysts BMY · Aug 17, 2026 iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone - (EXCALIBER RRMM) — Relapsed/refractory multiple myeloma (RRMM) FDA decision history (9) Jun 1, 2026✓ Approved Camzyos (mavacamten) - (SCOUT- Mar 20, 2026✓ Approved Opdivo in combination with AVD Mar 6, 2026✓ Approved Sotyktu (deucravacitinib) - (P Dec 4, 2025✓ Approved FDA decision Jun 27, 2025✓ Approved FDA decision Jun 12, 2025✕ CRL FDA decision May 23, 2025✕ CRL FDA decision Apr 11, 2025✓ Approved FDA decision Apr 8, 2025✓ Approved FDA decision See the full 2026 PDUFA calendar → This page aggregates BMY's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio